Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active
in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I
dose-escalation study.
Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J,
Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
modis@mskcc.org
CONCLUSION:
Tanespimycin plus trastuzumab is well tolerated and has antitumor activity in patients with HER-2+ breast cancer whose tumors have progressed during treatment with trastuzumab. These data suggest that Hsp90 function can be inhibited in vivo to a degree sufficient to cause inhibition of tumor growth.
Source:
http://www.ncbi.nlm.nih.gov/sites/en...ubmed_RVDocSum
Linear Mode
